Abbott Laboratories is reportedly offering a Kaletra (lopinavir/ritonavir) price cut to the Thai government in order to block its threat to break the company’s patent on the HIV drug and import a generic version. According to the Xinhua news agency, the offer involves cutting the cost of the drug from $347 to $167 a month, the price Abbott currently offers to lower-middle-income countries.